PDF(Pubmed)
Abstract：
UNASSIGNED: Anticoagulation is recommended for stroke prevention in patients with atrial fibrillation (AF). The guidelines suggest non-vitamin K antagonist anticoagulants (NOACs) as the primary therapy for anticoagulation in AF. Several patient-related factors increase the risk of thrombotic events: elderly individuals, a previous history of stroke, and chronic kidney disease. This study aims to determine the association between NOACs and other patient variables in AF and the occurrence of thrombotic events.
UNASSIGNED: The database included all adults with the code K78 (ICPC-2 code for AF) who received clinical care in Northern Portugal\'s Primary Health Care between January 2016 and December 2018 and were dispensed the same NOAC at the pharmacy.
UNASSIGNED: The results indicate that 10.2% of AF patients on NOAC anticoagulation experienced a stroke. Furthermore, patients treated with apixaban and dabigatran had higher odds of experiencing a stroke compared to those treated with rivaroxaban. Among patients with the same age, gender, and CHA2DS2Vasc Score, apixaban was significantly associated with a higher likelihood of thrombotic events than rivaroxaban.
UNASSIGNED: These results have not been previously reported in studies with real-world data; therefore, a more detailed analysis should be conducted to enhance the validity of these findings.
UNASSIGNED: The database included all adults with the code K78 (ICPC-2 code for AF) who received clinical care in Northern Portugal\'s Primary Health Care between January 2016 and December 2018 and were dispensed the same NOAC at the pharmacy.
UNASSIGNED: The results indicate that 10.2% of AF patients on NOAC anticoagulation experienced a stroke. Furthermore, patients treated with apixaban and dabigatran had higher odds of experiencing a stroke compared to those treated with rivaroxaban. Among patients with the same age, gender, and CHA2DS2Vasc Score, apixaban was significantly associated with a higher likelihood of thrombotic events than rivaroxaban.
UNASSIGNED: These results have not been previously reported in studies with real-world data; therefore, a more detailed analysis should be conducted to enhance the validity of these findings.
摘要：
■建议抗凝用于预防房颤（AF）患者的卒中。指南建议非维生素K拮抗剂抗凝剂（NOAC）作为房颤抗凝的主要治疗方法。几个患者相关因素增加血栓事件的风险：老年人，以前的中风史，和慢性肾病。本研究旨在确定NOAC和其他房颤患者变量与血栓事件发生之间的关联。
该数据库包括代码为K78（AF的ICPC-2代码）的所有成年人，他们在2016年1月至2018年12月期间在葡萄牙北部的初级卫生保健机构接受了临床护理，并在药房分配了相同的NOAC。
■结果表明，接受NOAC抗凝治疗的房颤患者中，有10.2%出现了中风。此外，与利伐沙班相比,接受阿哌沙班和达比加群治疗的患者发生卒中的几率更高.在相同年龄的患者中，性别,和CHA2DS2Vasc评分，与利伐沙班相比,阿哌沙班与更高的血栓事件发生可能性显著相关.
■这些结果以前没有在现实世界数据的研究中报道过；因此，应该进行更详细的分析，以提高这些发现的有效性。
该数据库包括代码为K78（AF的ICPC-2代码）的所有成年人，他们在2016年1月至2018年12月期间在葡萄牙北部的初级卫生保健机构接受了临床护理，并在药房分配了相同的NOAC。
■结果表明，接受NOAC抗凝治疗的房颤患者中，有10.2%出现了中风。此外，与利伐沙班相比,接受阿哌沙班和达比加群治疗的患者发生卒中的几率更高.在相同年龄的患者中，性别,和CHA2DS2Vasc评分，与利伐沙班相比,阿哌沙班与更高的血栓事件发生可能性显著相关.
■这些结果以前没有在现实世界数据的研究中报道过；因此，应该进行更详细的分析，以提高这些发现的有效性。
